Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;205(5):1810-1814.
doi: 10.1111/bjh.19698. Epub 2024 Aug 7.

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy

Samantha A Hershenfeld  1 , Josuha W D Tobin  2   3 , Victoria Shelton  1 , Lourdes Calvente  1 , Katherine Lajkosz  1 , Ting Liu  1 , Marianne Brodtkorb  4 , Francesco Annibale d'Amore  5 , Maja Ludvigsen  5   6 , Tara Baetz  7 , David LeBrun  8 , Nathalie Johnson  9 , Michael Crump  1 , Michael Hong  1 , John Kuruvilla  1 , Rosemarie Tremblay-LeMay  1 , Michael MacManus  10 , Richard Tsang  1 , David C Hodgson  1 , Maher K Gandhi  2   3 , Robert Kridel  1
Affiliations

Single gene mutations and prognosis in limited-stage follicular lymphoma treated with radiation therapy

Samantha A Hershenfeld et al. Br J Haematol. 2024 Nov.

Abstract

Radiotherapy is routinely used for management of limited-stage follicular lymphoma (FL), yet half of patients ultimately relapse. We hypothesized that the presence of specific gene mutations may predict outcomes. We performed targeted sequencing of a 69-gene panel in 117 limited-stage FL patients treated with radiotherapy and identified recurrently mutated genes. CREBBP was most frequently mutated, and mutated CREBBP was associated with inferior progression-free survival, though not after false discovery rate adjustment. This association failed to validate in an independent cohort. We conclude that recurrent gene mutations do not predict outcomes in this setting. Alternative biomarkers may offer better prognostic insight.

Keywords: genetics; non‐Hodgkin lymphoma; prognostic factors; radiotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Dreyling M, Ghielmini M, Rule S, Salles G, Vitolo U, Ladetto M, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27(suppl 5):v83–v90.
    1. Kuruvilla J, Assouline S, Hodgson D, MacDonald D, Stewart D, Christofides A, et al. A Canadian evidence‐based guideline for the first‐line treatment of follicular lymphoma: joint consensus of the lymphoma Canada scientific advisory board. Clin Lymphoma Myeloma Leuk. 2015;15(2):59–74.
    1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B‐Cell Lymphomas, V.5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [November 1, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org.
    1. Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F‐FDG PET‐CT: a collaborative study by ILROG. Blood. 2019;133(3):237–245.
    1. Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long‐term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–3806.

LinkOut - more resources